To investigate the prevalence and prognostic impact of non-ITD mutations in the FLT3 JMD of adult patients with AML, we analyzed a large cohort of 1,539 patients with newly diagnosed AML to correlate these mutations with clinical characteristics, co-mutations, and outcome. The gene discussed is FLT3; the disease is acute myeloid leukemia.